{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:51:03Z","timestamp":1791517863186,"version":"4.3.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The therapeutic landscape of pediatric ulcerative colitis (UC) has evolved substantially with the introduction of multiple advanced therapies, creating new challenges in selecting the most appropriate initial treatment. While infliximab has long served as the reference biologic, biologics with different mechanisms of action and small-molecule therapies have expanded therapeutic options. However, the pediatric evidence supporting first-line advanced therapy remains heterogeneous across currently available agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review critically summarizes the current pediatric evidence supporting first-line advanced therapies for UC, focusing on anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, selective interleukin-23 inhibitors, and other emerging advanced therapies. We evaluate the maturity, characteristics, and direct applicability of the available evidence to biologic-na\u00efve pediatric patients and discuss the major limitations of the current literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among currently available therapies, anti\u2013tumor necrosis factor therapy, particularly infliximab, is supported by the most comprehensive prospective pediatric evidence. In contrast, evidence for vedolizumab, ustekinumab, and selective IL-23 inhibitors has accumulated more recently and remains comparatively limited. Across all therapeutic classes, direct comparative studies in biologic-na\u00efve pediatric patients are lacking, and evidence supporting individualized treatment selection remains insufficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current pediatric evidence supports the efficacy of multiple advanced therapies and has characterized important safety outcomes; however, evidence establishing therapeutic efficacy should be distinguished from evidence directly informing first-line treatment selection. Future pediatric research should increasingly generate comparative and predictive evidence that informs which effective advanced therapy should be selected first and for whom.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag203","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:37:51Z","timestamp":1790077071000},"source":"Crossref","is-referenced-by-count":0,"title":["Current evidence for first-line advanced therapies in pediatric ulcerative colitis: a critical review"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-5522","authenticated-orcid":false,"given":"Toshihiko","family":"Kakiuchi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Saga University , Saga,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100823332124800_izag203-B1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/jpn3.70097","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care\u2014an updated evidence-based consensus guideline from ESPGHAN and ECCO","volume":"81","author":"Wine","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026100823332124800_izag203-B2","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/ajg.2009.177","article-title":"The natural history of pediatric ulcerative colitis: a population-based cohort study","volume":"104","author":"Gower-Rousseau","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2026100823332124800_izag203-B3","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","article-title":"Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response","volume":"138","author":"Turner","year":"2010","journal-title":"Gastroenterology"},{"key":"2026100823332124800_izag203-B4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/S0140-6736(18)32592-3","article-title":"Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study","volume":"393","author":"Hyams","year":"2019","journal-title":"Lancet"},{"key":"2026100823332124800_izag203-B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12887-019-1739-5","article-title":"Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan","volume":"19","author":"Tajiri","year":"2019","journal-title":"BMC Pediatr"},{"key":"2026100823332124800_izag203-B7","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1016\/S1590-8658(08)60535-6","article-title":"Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study","volume":"40","author":"Cucchiara","year":"2008","journal-title":"Dig Liver Dis."},{"key":"2026100823332124800_izag203-B8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/MCG.0b013e3181354417","article-title":"Infliximab for ulcerative colitis in children and adolescents","volume":"42","author":"McGinnis","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"2026100823332124800_izag203-B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5223\/pghn.2014.17.1.31","article-title":"Clinical course of infliximab treatment in Korean pediatric ulcerative colitis patients: a single center experience","volume":"17","author":"Kim","year":"2014","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"2026100823332124800_izag203-B10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5223\/pghn.2025.28.3.166","article-title":"Long-term response durability of infliximab for pediatric inflammatory bowel disease in Japan: a single center experience","volume":"28","author":"Tsumura","year":"2025","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"2026100823332124800_izag203-B11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/ibd\/izaf322","article-title":"Efficacy, safety, and pharmacokinetics of golimumab in children with moderately-to-severely active ulcerative colitis: results from the PURSUIT 2 study","volume":"32","author":"Turner","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"2026100823332124800_izag203-B13","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/ecco-jcc\/jjx082","article-title":"Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto Group of ESPGHAN","volume":"11","author":"Ledder","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026100823332124800_izag203-B14","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00431-021-04063-6","article-title":"Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study","volume":"180","author":"Garcia-Romero","year":"2021","journal-title":"Eur J Pediatr"},{"key":"2026100823332124800_izag203-B15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.clinthera.2022.06.004","article-title":"Vedolizumab as the first-line of biologicals for pediatric patients with ulcerative colitis","volume":"44","author":"Kakiuchi","year":"2022","journal-title":"Clin Ther"},{"key":"2026100823332124800_izag203-B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/jgh.16246","article-title":"Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan","volume":"38","author":"Yokoyama","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2468-1253(24)00319-4","article-title":"Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study","volume":"10","author":"Atia","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B19","doi-asserted-by":"publisher","first-page":"jjaf231.074","DOI":"10.1093\/ecco-jcc\/jjaf231.074","article-title":"DOP037 efficacy and safety of intravenous vedolizumab in paediatric patients with moderate-to-severe ulcerative colitis: results from the KEPLER phase 3 trial","volume":"20","author":"Turner","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026100823332124800_izag203-B20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12887-022-03229-x","article-title":"Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review","volume":"22","author":"Fang","year":"2022","journal-title":"BMC Pediatr"},{"key":"2026100823332124800_izag203-B21","doi-asserted-by":"crossref","first-page":"17562848251356063","DOI":"10.1177\/17562848251356063","article-title":"A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights","volume":"18","author":"Abu Hammour","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"2026100823332124800_izag203-B22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.16388","article-title":"One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study","volume":"53","author":"Dhaliwal","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100823332124800_izag203-B23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40272-024-00631-z","article-title":"Effectiveness and safety of ustekinumab in pediatric ulcerative colitis: a multi-center retrospective study from the pediatric IBD Porto Group of ESPGHAN","volume":"26","author":"Cohen","year":"2024","journal-title":"Paediatr Drugs"},{"key":"2026100823332124800_izag203-B24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/jpn3.12169","article-title":"Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis","volume":"78","author":"Patel","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026100823332124800_izag203-B25","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/jpn3.70163","article-title":"Long-term effects of ustekinumab in children with inflammatory bowel disease: a systematic review","volume":"81","author":"Marques","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026100823332124800_izag203-B26","doi-asserted-by":"publisher","first-page":"jjaf231.1335","DOI":"10.1093\/ecco-jcc\/jjaf231.1335","article-title":"P1154 safety and efficacy of ustekinumab in paediatric ulcerative colitis (UC): results from the phase 3 UNIFI Jr study","volume":"20","author":"De Greef","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026100823332124800_izag203-B27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S2468-1253(25)00196-7","article-title":"Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial","volume":"11","author":"Kaplan","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/ibd\/izaf291","article-title":"Real-world effectiveness of and optimization strategies for mirikizumab in pediatric ulcerative colitis: a prospective, observational study","volume":"32","author":"Jimbo","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"2026100823332124800_izag203-B29","doi-asserted-by":"crossref","first-page":"jjae182","DOI":"10.1093\/ecco-jcc\/jjae182","article-title":"Upadacitinib for induction of remission in pediatric ulcerative colitis: an international multicenter study","volume":"19","author":"Yerushalmy-Feler","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026100823332124800_izag203-B30","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.cgh.2026.02.012","article-title":"Upadacitinib maintenance therapy in pediatric ulcerative colitis: 52-week multicenter study from the Porto group of ESPGHAN","volume":"24","author":"Yerushalmy-Feler","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ibd\/izae112","article-title":"Tofacitinib in pediatric ulcerative colitis: a retrospective multicenter experience","volume":"31","author":"Ledder","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026100823332124800_izag203-B32","author":"U.S. Food and Drug Administration","year":"2026"},{"key":"2026100823332124800_izag203-B33","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B34","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B35","author":"U.S. Food and Drug Administration"},{"key":"2026100823332124800_izag203-B36","author":"U.S. Food and Drug Administration"},{"key":"2026100823332124800_izag203-B37","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"2026100823332124800_izag203-B38","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"2026100823332124800_izag203-B39","author":"U.S. Food and Drug Administration"},{"key":"2026100823332124800_izag203-B40","author":"U.S. Food and Drug Administration","year":"2026"},{"key":"2026100823332124800_izag203-B41","author":"U.S. Food and Drug Administration"},{"key":"2026100823332124800_izag203-B42","year":"2026"},{"key":"2026100823332124800_izag203-B43","author":"European Medicines Agency","year":"2026"},{"key":"2026100823332124800_izag203-B44","author":"European Medicines Agency","year":"2026"},{"key":"2026100823332124800_izag203-B45","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B46","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B47","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B48","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B49","author":"European Medicines Agency"},{"key":"2026100823332124800_izag203-B50","first-page":"110","article-title":"Guidelines for the treatment of pediatric ulcerative colitis (2019) [in Japanese]","volume":"33","author":"Abukawa","year":"2019","journal-title":"Nihon Shoni Eiyo Shokaki Kanzo Gakkai Zasshi"},{"key":"2026100823332124800_izag203-B51","author":"Shimizu","year":"2023"},{"key":"2026100823332124800_izag203-B52","author":"North American Society for Pediatric Gastroenterology, Hepatology and Nutrition"},{"key":"2026100823332124800_izag203-B53","doi-asserted-by":"publisher","first-page":"634739","DOI":"10.3389\/fped.2021.634739","article-title":"Predicting therapeutic response in pediatric ulcerative colitis\u2014a journey towards precision medicine","volume":"9","author":"Colman","year":"2021","journal-title":"Front Pediatr"},{"key":"2026100823332124800_izag203-B54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/j.gastro.2020.07.066","article-title":"Predicting outcomes in pediatric ulcerative colitis for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program","volume":"160","author":"Orlanski-Meyer","year":"2021","journal-title":"Gastroenterology"},{"key":"2026100823332124800_izag203-B55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/apt.17544","article-title":"Validation of predictive models for disease outcomes in paediatric ulcerative colitis: a multicentre prospective inception cohort","volume":"58","author":"Atia","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100823332124800_izag203-B56","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00535-025-02216-0","article-title":"First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study","volume":"60","author":"Naganuma","year":"2025","journal-title":"J Gastroenterol"},{"key":"2026100823332124800_izag203-B57","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.cgh.2021.07.038","article-title":"Comparative efficacy for infliximab vs vedolizumab in biologic na\u00efve ulcerative colitis","volume":"20","author":"Narula","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100823332124800_izag203-B58","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/apt.18441","article-title":"Long-term outcomes of an infliximab-first versus vedolizumab-first treatment strategy in biologic-na\u00efve patients with ulcerative colitis","volume":"61","author":"Haynesworth","year":"2025","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag203\/71734961\/izag203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag203\/71734961\/izag203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:33:34Z","timestamp":1791516814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag203\/8889159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag203","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"article-number":"izag203"}}